136
Participants
Start Date
February 5, 2014
Primary Completion Date
September 5, 2016
Study Completion Date
September 5, 2016
Mepolizumab
Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
Placebo
Placebo will be available as 0.9% sodium chloride
GSK Investigational Site, Brussels
GSK Investigational Site, Marseille
GSK Investigational Site, Philadelphia
GSK Investigational Site, Milan
GSK Investigational Site, Milan
GSK Investigational Site, Bethesda
GSK Investigational Site, Hamburg
GSK Investigational Site, Bad Bramstedt
GSK Investigational Site, Montpellier
GSK Investigational Site, Fulda
GSK Investigational Site, Cleveland
GSK Investigational Site, Florence
GSK Investigational Site, Rochester
GSK Investigational Site, Pisa
GSK Investigational Site, Bron
GSK Investigational Site, Kirchheim unter Teck
GSK Investigational Site, Paris
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Denver
GSK Investigational Site, Salt Lake City
GSK Investigational Site, Suresnes
GSK Investigational Site, Boston
GSK Investigational Site, Boston
GSK Investigational Site, Hamilton
GSK Investigational Site, Toronto
GSK Investigational Site, Jena
GSK Investigational Site, Kanagawa
GSK Investigational Site, Miyagi
GSK Investigational Site, Barcelona
GSK Investigational Site, Cambridge
GSK Investigational Site, Leicester
GSK Investigational Site, Portsmouth
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
GlaxoSmithKline
INDUSTRY